Latest research on Betaseron

Human interferon beta (165 residues), cysteine 17 is substituted with serine. Produced in E. coli, no carbohydrates, MW=18.5kD

Betaseron dosage

Relatively few head-to-head studies have been conducted among the BRACE therapies and discussion here is confined to those involving IFN beta-1b: versus IFN beta-1a IM, the Independent Comparison of Interferons (INCOMIN) trial [40]; versus IFN beta-1a SC [41]; versus IFN beta-1a both IM and SC [42]; and versus GA, the Betaferon Efficacy Yielding Outcomes of a New Dose (BEYOND; #NCT00099502) trial [43] and the Betaseron versus Copaxone in Multiple Sclerosis with Triple-Dose Gadolinium and 3-Tesla MRI Endpoints (BECOME; #NCT00176592) trial [44]. [source, 2014]
The BEYOND study compared two different doses of IFN beta 1b (Betaseron) versus glatiramer. [source, 2014]
Twenty-five RRMS patients treated with IFN-β (Avonex, Biogen Idec; Betaseron, Bayer Healthcare, Wayne, NJ; Rebif, EMD Serono, Rockland, MA; all at recommended doses) for >1 year and 25 untreated RRMS patients were included as controls (cohort 1; Table 1). [source, 2014]
If the patients do not respond to Avonex therapy and show disease progression, the treatment regimen can be changed to higher doses of interferon beta (Rebif or Betaseron) or glatiramer acetate. [source, 2013]
Six of the seven patients had received high-dose, high-frequency Betaseron IFNβ-1b therapy for >3 years. [source, 2013]
Three different formulations of beta-interferons which exist for treatment of MS consist of low dose IFN-β1a (Avonex) (30 micrograms intramuscular once weekly), high disease IFN-β1a [Rebif] (22 and 44 micrograms subcutaneously three times weekly), and IFN-β1b (Betaseron) (8,000,000 units 250 micrograms subcutaneously alternate day injection). [source, 2013]
Due to the difference in frequency of administration and the utilized dose, Avonex is known as “low dose” β-interferon, while Rebif and Betaseron are recognized as “high dose. [source, 2013]
Current dosing allows for either low (22 μg) or high (44 μg) dose Interferon beta 1a (Rebif®) subcutaneous three time weekly, and one dose of each of Interferon beta 1b (Betaseron) 250 mcg subcutaneous, every other day, and Interferon beta 1a (Avonex®) 30 mcg intramuscularly once per week. [source, 2012]
More recently, in the BECOME (Betaseron vs. Copaxone in MS with Triple-Dose Gadolinium and 3-T MRI Endpoints) study, the effect of IFN-β-1b and GA on new active lesions was tested on the 3 T optimized protocol (3 T MRI scanner, a triple dose of Gd, with a 20-min scanning time delay after Gd injection) in 75 patients with relapsing-remitting (RR) MS who underwent serial monthly MRI scans over 12 months [20]. [source, 2012]
The BEYOND (Betaseron Efficacy Yielding Outcomes of a New Dose) study compared 3 treatment groups (N = 2244 in a 2:2:1 randomization): 250 μg of IFNβ-1b SC (Betaseron®, Bayer HealthCare Pharmaceuticals, Montville, NJ, USA) dosed every other day; IFNβ-1b 500 μg SC dosed every other day; GA 20 mg SC daily over ≥2 years. [source, 2010]